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1. Introduction  
1.1 Do we need biological markers for Parkinson’s disease?  
In the recent years increasing attention on biomarkers for neurodegenerative diseases, 
including Parkinson’s disease (PD), has been paid.  
The reasons of this growing tendency are several: 
(i) PD is one of the most common neurodegenerative diseases, affecting approximately 1% 
of people over 60 years of age (Samii et al., 2004). Diagnosis of PD is based on clinical 
criteria, relying on motor features: rigidity, bradykinesia, resting tremor and in the late 
stages postural instability (Hughes et al., 1992). However, clinical diagnosis especially in the 
early stages of disease can be challenging owing to the difficult differential diagnosis with 
essential tremor and atypical parkinsonism, namely multiple system atrophy (MSA), 
progressive sopranuclear palsy (PSP), and corticobasal degeneration (CBD). Although in 
movement disorder specialized settings the diagnostic accuracy is satisfactory (≥80%), 
almost one third of the clinical diagnoses in patients with parkinsonism is revised in the first 
five years of disease (Hughes et al., 2002). Diagnostic accuracy in the early stages of disease 
is important, in view of forthcoming disease-modifying therapies (Olanow et al., 2008). In 
this perspective, diagnostic biomarkers are urgently needed. (ii) Also, there is the need for 
progression biomarkers, ie, parameters reflecting a feature associated with disease- severity 
(Maetzler  et al., 2009). (iii) Finally, PD per se is a heterogeneous disease, with different 
clinical phenotypes (the akinetic-rigid type vs. the tremor dominant variant) and different 
etiologies (genetic vs. sporadic form), which might have different progression rate, 
prognosis, thus requiring different therapeutic approaches. PD is not merely a motor 
disorder.  
Recently, great attention has been drawn to non-motor symptoms, namely cognitive decline, 
behavioural changes, sleep disorders and autonomic dysfunction, due to their relevant 
impact on quality of life of parkinsonian patients (Chaudhuri et al., 2006). Both in early and 
in advanced stages, these symptoms represent a challenge in the clinical management of PD 
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patients. Among non-motor features, i.e. hyposmia and R.E.M. sleep behavior disorders 
(RBD), cognitive decline dramatically changes the prognosis of disease. In this perspective, a 
biomarker distinguishing parkinsonian patients who will develop cognitive decline from 
those who will not, would have a great impact. Moreover, cognitive performances are 
impaired not only in PD but also in other parkinsonism, such as PSP or dementia with Lewy 
bodies (DLB), and again a biomarker differentiating these neurodegenerative diseases is 
required. 
In order to develop a specific and successful treatment, the tendency to group together 
parkinsonism solely on a clinical ground should be replaced by the systematic use of reliable 
and validated biomarkers as the peripheral expression of the underlying pathogenetic 
mechanisms (Schlossmacher and Mollenhauer, 2010). In medicine biomarkers have different 
purposes: to identify subjects at risk of developing a certain disease (marker of trait); to 
identify the manifestation of disease (marker of state); to reflect the progression of disease 
(progression marker); to predict the onset of disease (marker of fate) (Schlossmacher and 
Mollenhauer, 2010). In this perspective, biomarkers are needed in order to reach an early 
and accurate PD diagnosis, also allowing a differential diagnosis between PD and other 
parkinsonism; to differentiate PD with dementia from Alzheimer’s disease (AD), DLB and 
other dementias; to differentiate between variants of PD; to monitor disease progression and 
treatment response (Nyhlén et al., 2010).  
An ideal biomarker should be sensitive, reproducible, closely associated to the disease 
process, easy to measure, inexpensive, non-invasive and thoroughly validated (Michell et 
al., 2004; van Dijk et al., 2010). Unfortunately such a marker is not available yet in PD. 
Potential biomarkers in PD include imaging markers, such as striatal dopamine transporter 
binding measured with single photon emission computed tomography (Isaias and Antonini, 
2010), transcranial ultrasound (Berg and Becker, 2002), or body fluid markers. Although 
many efforts have been made to detect reliable biomarkers in blood and urine, the most 
promising source of biomarkers is cerebrospinal fluid (CSF). The main advantage of CSF is 
its direct contact with brain so that it is thought that biochemical alterations in the brain are 
reflected in CSF. This is one of the reasons why CSF is the main source of biomarkers also in 
other neurodegenerative diseases, such as Alzheimer’s disease, where it has become of 
support in early diagnosis (Dubois et al., 2007; Dubois et al., 2010).  
This chapter will be dedicated to candidate CSF biomarkers in PD. However, some 
considerations should be taken in account while reviewing CSF studies in 
neurodegenerative disease and specifically in PD. CSF proteins pool is formed by a main 
part of blood-derived proteins and a minor part of brain tissue protein (Mollenhauer and 
Trenkwalder, 2009; van Dijk et al., 2010). Special attention should be driven on technical 
aspects in the collection of CSF, particularly to avoid blood contamination during lumbar 
puncture, which can enormously increase CSF content of protein owing to the high 
concentration of proteins in blood (Hong et al., 2010), and to limit circadian fluctuations of 
protein concentrations (Nilsson et al., 1992).  
In this section we will consider -synuclein, the main component of Lewy bodies; molecules 
expressing mitochondrial dysfunction and oxidative stress, such as DJ-1, and other oxidative 
stress related proteins; molecules reflecting impaired protein degradation, protein 
aggregation and LBs formation, such as protein tissue transglutaminase, osteopontine, and 
neurofilaments; molecules reflecting inflammation, glial activation, apoptosis and cell death. 
Also, classical CSF AD biomarkers - ǃ-amyloid1-42 (Aǃ1-42) , total tau, hyperphosphorylated 
tau – and their correlation with cognitive impairment in PD will be discussed. 
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2. Alpha-synuclein as disease-state marker 
The neuropathological hallmarks of PD are the loss of pigmented neurons in the substantia 
nigra pars compacta (SNpc) and the Lewy bodies, LBs (Braak et al., 2003). LBs are 
intraneuronal spherical inclusions, which appear eosinophilic with a dense core surrounded 
by a halo at hematoxylin/eosin staining (Shults, 2006). LBs’ main component is -synuclein (-
syn), a 140-amino acids protein mainly located in the presynaptic terminals of most neurons. It 
is a member of a highly conserved family of proteins consisting of -, ǃ-, and Ǆ-syn (Spillantini 
et al., 1997, Eriksen et al., 2003). Alpha-syn consists of: i) the N-terminal region, which contains 
a number of imperfect repeats, with the consensus motif KTKEGV; ii) the central hydrophobic 
region, called NAC (non-amyloid component), suggested to be responsible for the aggregation 
process (Giasson et al., 2001); and iii) the acidic C-terminal region involved in the regulation of 
fibril formation (Murray et al., 2003). Several studies suggest that -syn exists in equilibrium 
between a cytosolic unfolded conformation and a membrane-bound, alpha-helical structure 
(Cole et al., 2002; McLean et al., 2000). Although its physiological function is still unknown, its 
localization and ability to interact with membranes suggest that -syn might play a role in 
vesicle dynamics and trafficking at the presynaptic terminal and in brain lipid metabolism 
(Willingham et al. 2003; Darios et al., 2010). 
Inclusions of -syn are neuropathological features also in other neurodegenerative diseases 
that, together with PD, form the spectrum of synucleinopathies. They include multiple 
system atrophy (MSA), an oligodendrogliopathy, and DLB, the most frequent cause of 
degenerative dementia after AD (Spillantini & Goedert, 2000; Galvin et al., 2001). The 
discovery of missense mutations (Polymeropoulos et al., 1997; Kruger et al., 1998; Zarranz et 
al., 2004) and multiplications (duplications and triplications) (Chartier-Harlin et al., 2004; 
Singleton et al., 2003) within the gene encoding -syn (SNCA) in familial case of PD has 
further increased the interest on this protein implicated in the etiopathogenesis of PD. More 
recently, SNCA polymorphisms have been associated with increased risk of sporadic PD 
and MSA, reinforcing the hypothesis of its implication in the etiopathogenesis of 
synucleinopathies (Simón-Sánchez et al., 2009; Satake et al., 2009; Scholz et al., 2009). Despite 
these evidences of a direct implication of -syn in the pathogenesis of PD, the mechanisms 
through which this happens are not so clear. The lack of pathological phenotype associated 
to -syn knock-out mice (Chandra et al., 2004) together with the observation of familial PD 
cases related to duplications/triplications of -syn, as well as the presence of -syn 
aggregates in PD brains, suggest for –syn a gain-of-function pathogenetic mechanism. In 
line with this view, it has been shown that -syn tends to aggregate into amyloid-like, beta-
sheet fibrils (Bisaglia et al., 2009) and fibrillization is increased in the presence of mutations 
or elevated protein levels (Conway et al., 2001; Li et al., 2001; Shtilerman et al., 2002). 
In PD and other synucleinopathies, -syn in its monomeric form tends to aggregate into 
insoluble fibrils. Soluble oligomers and -syn protofibrils, the intermediate stages in the 
development of these aggregates, are considered to be the toxic forms of -syn (El-Agnaf et 
al., 2003a). Several factors such as phosphorylation at Ser129, decrease in pH, temperature 
increase, presence of metal ions and small charged molecules influence fibril formation and 
aggregation (Uverski 2007). Aggregation of -syn can be promoted also by the protein tissue 
transglutaminase, which induces crosslinkings (Junn et al., 2003).   
Alpha-syn degradation is mediated mainly through proteasomal system and autophagy 
pathway via lysosomes. Self-digestion of protein via lysosomes activity can occur in a 
chaperon-dependent or -independent way (Cuervo et al., 2004; Shin et al., 2005; Lee et al., 
2005).  
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3. Is CSF alpha-syn a diagnostic marker of PD and other synucleynopathies? 
Several studies have detected -syn in human biological fluids, including plasma and CSF 
(El-Agnaf et al., 2003b; Lee et al., 2005; Mollenhauer et al., 2008; Mollenhauer et al., 2010). 
More recently attention has been focused on CSF -syn as potential biomarker (see table 1).  
The presence of -syn in the CSF was first reported in 2000 using an immunoprecipitation 
and immunoblotting approach with the limit of low specificity (Borghi et al. 2000). In 
another study CSF collected at autopsy was analyzed, thus raising the concern of a possible 
increase of -syn due to autolysis (El-Agnaf et al., 2003b). Finally the proof of the presence of 
-syn in CSF was provided using affinity enrichment of CSF followed by mass spectrometry 
(Mollenhauer et al., 2008). In the last years, several studies on CSF -syn as potential 
biomarker of synucleinopathy have been published, but the results have remained so far 
inconclusive, mainly owing to differences in sample handling and in measurement methods. 
The wide range of absolute concentration reported even in the same group of patients has 
been a hindrance to the interpretation of results (Mollenhauer et al., 2010). Another concern 
is the possible contamination of CSF sample with blood during lumbar puncture. Indeed, 
since levels of -syn stored in human blood cells are much higher than in CSF, minimal 
contamination of CSF with blood may increase CSF -syn concentration (Hong et al., 2010). 
Neither rostrocaudal gradient nor diurnal fluctuations of -syn CSF concentrations have 
been found so far (Hong et al., 2010; Mollenhauer et al., 2010). Other possible confounders in 
CSF -syn levels are age and total CSF protein content. These parameters have been only 
partially investigated. Some studies have shown some negative correlation of -syn with age 
(Mollenhauer et al., 2008; Tokuda et al., 2006; Ohrfelt et al., 2009; Noguchi-Shinohara et al., 
2009; Parnetti et al., 2011), whereas one study (Hong et al., 2010) reported an opposite trend. 
In some studies reduced levels of -syn in CSF from PD and DLB have been detected 
compared to controls or AD (Tokuda et al., 2006; Mollenhauer et al., 2008; Tokuda et al., 
2010; Kasuga et al., 2010; Hong et al., 2010; Parnetti et al., 2011). Conversely, in other studies 
no significant difference between groups was observed (Öhrfelt et al., 2009; Noguchi-
Shinohara et al., 2009; Spies et al., 2009).  
Recently we investigated CSF concentration of -syn and classical CSF biomarkers - Aǃ1-42, 
total tau, phosphorylated tau - in patients with PD (n. 38), DLB (n. 32), AD (n. 48), 
frontotemporal dementia (n. 31) and in age-matched controls (n. 32). Results show that -
syn are significantly lower in all pathological groups as compared to controls, whereas the 
total tau/-syn and phosphorylated tau/-syn ratios were significantly lower only in PD. 
Our study supports that -syn alone has a low specificity for PD, but a better performance 
can be achieved with the ratio total tau/-syn (Parnetti et al., 2011). This finding strengthens 
the need of measuring different biomarkers in order to better know the neurochemical 
profile of neurodegenerative diseases. 
To shed further light into this complex scenario a large study including 721 patients has 
been recently published (Mollenhauer et al., 2011). In this study CSF -syn and tau levels 
were measured in both synucleinopathies (PD, DLB, MSA) and tauopathies (AD, PSP). The 
study has been conducted in three cohorts of patients: a “training set” from the collaboration 
of three centres; a validation cohort; and an-autopsy-confirmed group of AD, DLB and 
controls (table 1). This work confirms that synucleinopathies are characterized by lower 
concentrations of CSF -syn. However, since the specificity of -syn alone is low, the 
combination of CSF -syn and tau increases the discriminative power for differentiating PD 
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Study Patients  Quantification methods Capturing Ab (binding site) Reading Ab (binding 
site) 
Tokuda et al., 2006 33 PD, 38 controls Direct sandwich ELISA  mAb  211 (aa 121-125) pAb FL-140 (fu
length) 
Mollenhauer et al., 2008 8 PD, 38 DLB, 13 AD, 8 
CJD, 13 controls 
Direct sandwich ELISA 
(384-well plates) 
pAb mSA-1 (full length) mAb Syn1 (aa 
Ohrfelt et al., 2009 15 DP, 15 DLB, 66 AD, 55 
healthy controls 
Indirect and amplified 
sandwich ELISA 
mAb Syn1 (aa 84-96) Syn 5d (aa 127-
Noguchi-Shinohara 
et al., 2009 
16 DLB, 21 AD Direct sandwich ELISA  mAb  211 (aa 121-125) pAb FL-140 (fu
length) 
Spies et al., 2009 40 DLB, 131 AD, 28 VaD, 
39 FTD 
Direct sandwich ELISA  mAb  211 (aa 121-125) pAb FL-140 (fu
length) 
Hong et al., 2010 117 PD, 50 AD, 132 healthy 
controls 
xMAP analysis mAb LB 509 (aa 115-124) mAb 211 (aa 12
Kasuga et al., 2010 34 DLB, 31 AD, 21 other 
dementias, 2 SNCA 
duplication 
Direct sandwich ELISA  mAb Syn1 (aa 84-96) pAb FL-140 (fu
length) 
Tokuda et al., 2010 32 PD, 18 control & 25 PD, 
35 AD, 18 PSP, 43 controls 
Direct sandwich ELISA 
(for α-syn oligomers 
ELISA 384-well plate) 
mAb  211 (aa 121-125) pAb FL-140 (fu
length) 
Parnettin  et al., 2011 38 PD, 32 DLB, 48 AD, 31 
FTD, 32 neurological 
controls 
Direct sandwich ELISA  mAb  211 (aa 121-125) pAb FL-140 (fu
length) 
Mollenhauer et al., 2011 721 pts from 3 cohorts: (a) 
62 AD, 76 controls, 55 DLB, 
51 PD, 29 AD; (b) 23 
controls, 22 NPH, 8 PSP, 66 
DLB, 273 PD, 15 MSA; (c) 
21 AD, 7 controls, 13 DLB 
Direct sandwich ELISA 
(384-well plates) 
mAb Syn1-BB  pAb mSA-1 (full 
length) 
w
w
w
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from the other neurodegenerative diseases. The major merits of the study by Mollenhauer 
and colleagues are the large sample size and the completeness of the range of 
synucleinopathies assessed, allowing us to be more confident of the interpretation of the 
results obtained by the measurement of total CSF -synuclein. It also confirms the reliability 
of the assay, fixing the cutoff value at 1.6 pg/µL—ie, lower levels strongly suggest the 
presence of a synucleinopathy. This achievement is likely to be fundamental to the 
systematic use of -synuclein as a biomarker in a clinical setting (Parnetti, 2011). 
Another perspective, which highlights the direction toward a combination of biomarkers 
rather than toward a single marker, is the combination of CSF total -syn and -syn 
oligomers, with the latter found increased in PD in two recent papers (Paleologou et al., 
2009; Tokuda et al., 2010). Whether -syn is a marker of trait or a marker of progression is 
under investigation. According to the knowledge so far collected no clear-cut correlation 
with disease duration or disease severity (Hong et al., 2010; Parnetti et al., 2011) has been 
highlighted, suggesting that decrease of CSF -syn is a marker of trait in synucleinopathies.  
4. Other possible CSF biomarkers of PD: CSF proteins reflecting PD 
pathogenesis 
Beyond -syn, several other proteins and molecules have been investigated as potential 
biomarkers in PD. Most of them reflect PD pathogenesis and are classified upon different 
pathogenetic mechanisms. 
4.1 Molecules expressing mitochondrial dysfunction and oxidative stress  
The evidences for the implication of mitochondrial dysfunction and increased oxidative 
stress in the pathogenesis of PD are several (Schapira, 2008; Van Dijk et al., 2010): (i) 
mitochondrial complex I activity is reduced in the substantia nigra (Schapira et al., 1989); (ii) 
MPTP and rotenone toxicity is mediated via mitochondrial complex I inhibition (Tipton & 
Singer, 1993; Betarbet et al., 2003); (iii) mitochondrial-related proteins, such as prohibitin, 
ATP synthase and superoxide dismutase (SOD2), are altered in the nigra and frontal cortex 
of PD patients (Ferrer et al., 2007); and (iv) some monogenic forms of PD are caused by 
mutations of DJ-1 (Bonifati et al., 2003), PINK-1 (Valente et al., 2004), LRRK2 (Paisán-Ruíz et 
al., 2004; Zimprich et al., 2004), all implicated in the mitochondrial function and oxidative 
stress (Lin & Beal, 2006).  
Thus, attention has been focused on markers linked to the mitochondrial dysfunction and 
oxidative stress.  
4.1.2 DJ-1 
CSF DJ-1 levels have been investigated in two studies, yielding opposite results (Waragai et 
al., 2006; Hong et al., 2010). Waragai et al. (2006) found increased CSF DJ-1 levels  (assessed 
by means of western blotting) in PD-patients (n. 40) as compared to controls (n. 38). More 
recently, in a larger study involving PD (n. 117), controls (n. 132) and AD (n. 50), using a 
multiplex technology, CSF DJ-1 concentrations were found to be decreased in the PD group 
(Hong et al., 2010). Similarly for what found for -syn, DJ-1 levels were influenced by blood 
contamination. Also CSF levels were correlated with age and not with disease severity 
(Hong et al., 2010). Divergent results in the two studies might be mostly due to different 
methods. 
www.intechopen.com
 
CSF Biomarkers in Parkinson’s Disease 
 
35 
4.1.3 Other oxidative stress related proteins 
Other oxidative stress related proteins have been investigated in the CSF of PD patients, 
with the limits of single observations, small sample size, inconclusive results and lack of 
disease specificity. 
Increased CSF concentration of nitrated manganese superoxide dismutase (Mn-SOD) in PD, 
AD and amyotrophic lateral sclerosis (ALS) have been reported (Aoyama et al., 2000). 
Another study investigating oxidative stress in PD, AD, ALS and Huntington’s disease (HD) 
found decreased Cu/Zn-dependent superoxide dismutase (SOD1) activity in all these 
diseases (Boll et al., 2008); also, an increase of modified forms of Cu/Zn-dependent SOD has 
been published (Guo et al., 2009). Other studies found reduced CSF concentration of 
ceruloplasmin and ferroxidase activity, the enzyme that catalyzes the conversion of Fe2+ in 
Fe3 (Boll et al., 1999; Boll et al., 2008; Abdi et al. 2006), whereas CSF transferrin levels where 
unchanged in PD (Loeffler et al., 1994; van Kamp et al., 1995). 
4.2 Impaired protein degradation  
Impaired protein degradation, leading to aggregation of misfolded, mutant and toxic 
variant of proteins, plays a key role in the pathogenesis of PD and neurodegenerative 
diseases. Two main systems are implicated in protein degradation, namely the lysosomal 
and the ubiquitin-proteasome systems. Autophagy is a crucial pathway for the degradation 
of -syn (Cuervo et al., 2004; Shin et al., 2005; Lee et al., 2005). In recent years a strong link 
between mutations in glucocerebrosidase gene (GBA), the gene implicated in Gaucher 
disease (GD), and PD has been discovered supporting the link between lysosomal system 
and pathogenesis of PD (DePaolo et al., 2009; Velayaty et al., 2010). GD is an autosomal 
recessive lipidosis resulting from a deficiency of glucocerebrosidase enzyme. The 
observation of patients with GD and parkinsonism (Tayebi et al., 2003, Goker-Alpan et al., 
2008), the increased rate of GBA mutations and polymorphism in PD patients (Sidransky et 
al., 2009) along with neuropathological findings in brain of GD patients with parkinsonism 
similar to PD and DLB, all strengthening this hypothesis. The deficit in GBA might act 
through an impaired degradation of proteins via lysosomes leading to abnormal protein 
aggregates and Lewy bodies formation. Moving from these observations, in the last years 
we studied the activities of CSF beta-glucocerebrosidase and others lysosomal enzymes, 
finding that alpha-mannosidase, beta-mannosidase, and more evidently glucorebrosidase, 
were significantly reduced in PD (Balducci et al., 2007) and, even more markedly, in DLB 
patients (Parnetti et al., 2009).  
4.3 Protein aggregation and Lewy body formation  
One of the neuropathological hallmarks of PD is inclusions of misfolded, mutant, and 
damaged proteins and the formation of Lewy bodies (LBs) and Lewy neurites (LN) (Shults, 
2006). The main component of LBs is -synuclein (-syn). As described previously, -syn 
tends to aggregate into toxic oligomers and -syn protofibrils, the intermediate stages of 
insoluble fibrils (El-Agnaf et al., 2003a). The aggregation of -syn is modulated by several 
factors and promoted by the protein tissue transglutaminase, a regulator of apoptosis that 
appears to modulate -syn oligomerization promoting crosslinkings. A study investigating 
CSF tissue transglutaminase levels in 54 PD-patients and in 34 controls found increased 
levels only in PD (Vermes et al., 2004). 
Several other proteins are present in Lewy bodies, such as osteopontin and neurofilaments. 
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Osteopontin is a protein involved in apoptosis and oxidative stress, identified in several 
neurodegenerative diseases, including AD (Simonsen et al., 2007) and shown to be increased 
in CSF of PD patients as compared to controls (Maetzler et al., 2007).  
Neurofilaments are component of the cytoskeleton. In PD both light and heavy chain 
neurofilaments have been shown to be unchanged compared to controls, whereas they have 
been found to be elevated in other parkisonism, including MSA and progressive 
sopranuclear palsy (PSP) (Abdo et al., 2007; Holmberg et al., 1998). These observations have 
suggested that neurofilaments might be a promising marker in the differential diagnosis of 
parkinsonism. 
4.4 Inflammation and glial activation  
Among the several molecular and cellular changes leading to cellular death in PD, 
neuroinflammatory mechanisms seem to play an important contribution (Hirsch & Hunot, 
2009). Post-mortem studies have shown microglial activation, astrogliosis, and lymphocytic 
infiltration in the nigra of PD patients (Mc Geer et al., 1988; Damier et al., 1993). Increased 
concentrations of TNF-, ǃ2-microglobulin, epidermal growth factor (EGF), transforming 
growth factor  (TGF-), TGF-ǃ1, and interleukins 1ǃ, 6 and 2 have been detected in the 
striatum of PD (Mogi et al., 1994a; Mogi et al., 1994b; Mogi et al., 1995a; Mogi et al., 1995b; 
Mogi et al., 1996a). Some CSF studies have tried to investigate the involvement of 
inflammatory mechanisms in PD. Increased levels of interleukins, including interleukin 1ǃ, 
interleukin-8 and 6, and decreased levels of components of complement have been detected 
in CSF of PD patients (Mogi et al., 1995a; Blum-Degen et al., 1995; Müller et al., 1998; 
Finehout et a., 2005; Guo et al., 2009). However, it is still unclear whether these changes are 
the cause or the consequence of neuronal degeneration (Hirsch & Hunot, 2009). Moreover, 
these changes are not disease specific, being shared by many neurodegenerative diseases. A 
recent study, carried out in a large cohort including PD (n. 126), MSA (n. 32), AD (n. 50), and 
controls (n. 137), showed significantly lower CSF levels of the cytokine Flt3 ligand in MSA 
patients as compared to PD subjects (Shi et al., 2011).  
4.5 Apoptosis and cell death   
Apoptosis is an important mechanism of cell death in neurodegenerative diseases, including 
PD, as supported by a neuropathological study showing apoptotic process in 8 out of 11 
midbrains from PD patients (Mochizuki et al., 1996). Moreover, the anti-apoptotic protein 
bcl-2, the apoptosis-signaling receptor Fas, and the Annexin V have been found to be 
increased in the substantia nigra of PD (Mogi et al. 1996b; Mogi et al., 1996c; Werner et al., 
2008). A CSF study showed lower levels of Annexin V in PD as compared to controls. This 
result was interpreted as the consequence of the consumption of this protein during 
neuronal apoptosis in PD (Vermes et al., 1999). CSF study targeting bcl2 and Fas have failed, 
since neither bcl2 nor Fas are measurable in CSF (Mogi et al. 1996b; Mogi et al. 1996c).   
5. Classical CSF biomarkers and risk of cognitive impairment in PD  
The prevalence of cognitive impairment in PD-patients is higher compared to general 
population (30%) even in early PD (Aarsland et al., 2009; Aarsland & Kurz 2010), and the 
risk of dementia dramatically increases over the course of disease occurring in up to 80% of 
patients after 20 years of follow-up (Hely et al., 2008). Cognitive impairment and dementia 
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represent one of the most disabling non-motor symptoms in PD, with a relevant impact on 
quality of life of patients and caregivers. The spreading of Lewy body pathology to 
neocortical regions altogether with AD-type pathology in terms of ǃ-amyloid deposits, have 
been implicated in the pathogenesis of cognitive decline in PD (Braak et al., 2005; Ballard et 
al., 2006), suggesting an interplay between synucleinopathies and tauopathies. Recently, a 
growing amount of investigations in PD has focused on CSF biomarkers traditionally used 
in AD, namely ǃ-amyloid1-42 (Aǃ 1-42), total tau, hyperphosphorylated tau, in order to 
improve the ability to detect risk for cognitive impairment and dementia (Sjögren et al., 
2002; Mollenhauer et al., 2006; Parnetti et al., 2008; Compta et al., 2009; Alves et al., 2010; 
Siderowf et al., 2010; Montine et al., 2010; Leverenz et al., 2011) (table 2). Tau protein, a 
microtubule associated protein, in its phosphorylated form represents the major component 
of the neurofibrillary tangles (Grundke-Iqbal et al., 1986). Increased CSF levels of tau and 
phosphorylated tau have been found to be specific markers for AD (Blennow et al., 1995). 
The different enzymatic cleavage of the 120kDa transmembrane amyloid precursor protein 
(APP) by three different secretases produces different ǃ-amyloid peptides (Glenner et al., 
1984). Beta-amyloid1-42 peptide (Aǃ 1-42), the main component of amyloid plaques in the 
brain of patients with AD and DLB, has been shown to be decreased in the CSF of AD 
patients for the first time in 1995 (Motter et al, 1995). These findings have lead to a revision 
of the National Institute of Neurological Disorders and Stroke-Alzheimer Disease and 
Related Disorders (NINCDS-ADRDA) criteria for the diagnosis of AD including CSF 
biomarkers (Dubois et al., 2007). Studies report normal CSF levels of tau and 
phosphorylated tau in PD (Blennow et al., 1995; Parnetti et al., 2008; Alves et al., 2010; Shi et 
al., 2010), whereas unchanged or slightly decreased levels of Aǃ 1-42 have been reported 
(Sjögren et al., 2002; Mollenhauer et al., 2006; Bibl et al., 2006; Parnetti et al., 2008; Compta et 
  
al., 2009; Alves et al., 2010; Siderowf et al., 2010; Montine et al., 2010; Leverenz et al., 2011; 
Shi et al., 2011). More recently, several studies have been published reporting a possible 
association between low Aǃ 1-42 levels and cognitive impairment in PD (Compta et al., 2009; 
Alves et al., 2010; Siderowf et al., 2010; Montine et al., 2010; Leverenz et al., 2011). Lower 
levels of CSF Aǃ 1-42 were found in 20 PD-patients with dementia compared to 20 PD-
patients and 30 controls, whereas higher concentrations of CSF tau and phosphorylated tau 
were associated with impaired memory and naming, suggesting an underlying AD 
pathology in PDD (Compta et al., 2009). A recent study compared CSF concentrations of 
Aǃ1-42, Aǃ1-40, Aǃ 1-38, total tau and phosphorylated tau in a large cohort of de novo and 
untreated PD-patients (n. 109), recruited from the Norwegian ParkWest study, with those of 
36 age-matched controls and 20 mild AD patients (Alves et al., 2010). In PD patients reduced 
levels of Aǃ 1-42, Aǃ 1-40, Aǃ 1-38 compared to controls were found. Authors showed also a 
significant association between CSF levels of Aǃ 1-42, Aǃ 1-40, Aǃ 1-38  and memory impairment. 
A recent prospective study in a cohort of 45 PD patients with 1-year follow-up showed that 
lower levels of Aǃ 1-42 at baseline were associated with a more rapid cognitive decline 
(Siderowf et al., 2010). Another recent study reported an association between low levels of 
Aǃ 1-42 levels in 22 non-demented PD patients and worse performance at Digit Symbol test 
(Leverenz et al., 2011). Although the limitations of these studies, including the small sample 
size, the heterogeneity of clinical features of patients, the lack of a group of control, the 
results are interesting and support the role of amyloid plaques in the pathogenesis of 
dementia in PD patients, in line with a recent report of altered in vivo amyloid imaging in 2 
autopsy-confirmed PDD patients (Burack et al., 2010). 
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Study Patients   CSF Aβ42 CSF T-tau CSF P-tau Relationship with 
cognitive impairment  
Parnetti 
et al., 
2008 
20 PD, 
18 PDD, 
19DLB, 
20 
controls  
CTRL>PD> 
PDD>DLB  
CTRL=PD 
DLB>PDD> 
PD  
 
CTRL=PD, 
PDD,DLB 
↓ Aǃ42 associated with ↓ 
performance at  Word 
Fluency and Prose 
Memory tests   
Compta 
et al., 
2009 
20 PD, 
20 PDD, 
30 
controls 
CTRL>PD> 
PDD 
CTRL=PD 
PDD>PD 
CTRL=PD 
PDD>PD 
↓ Aǃ42 in patients with ↓ 
performance at Verbal 
Fluency test 
Siderowf 
et al., 
2010 
45 PD, 
no 
controls 
= = = = = = = = = ↓ baseline Aǃ42  
associated with faster 
cognitive decline (↓Aǃ42 
independent predictor of 
cognitive decline) 
Alves  
et al., 
2010 
109 de 
novo PD, 
36 
controls  
PD<CTRL CTRL=PD CTRL=PD ↓ Aǃ42 associated with  
poorer performances on 
memory tests 
Leverenz 
et al., 
2011 
22 PD, 
no 
controls 
= = = = = = Not 
measured 
Association between 
↓Aǃ42 and/or Aǃ42/T-
tau and ↓ performance at 
Digit Symbol and 
Category Fluency tests 
Table  2. CSF Aǃ42 and cognitive impairment in PD. 
6. Conclusions and perspectives 
Neurodegenerative diseases, including PD, are common and become more common with 
increasing age. At present, diagnosis substantially relies on clinical criteria, which makes it 
difficult to achieve an accurate early diagnosis. Moreover, it is not rare that in an elderly 
patient two or more neurodegenerative diseases, as well as cerebrovascular changes, coexist 
(Nyhlen et al., 2010). It is also possible that conceptually distinct disease processes may 
reinforce or modify each other. For example, -syn aggregation may promote Ab 
aggregation and vice versa; also, tau has been shown to interact with -syn, promoting its 
fibrillization. It can be claimed that PD- and AD-like changes often occur simultaneously, 
contribute to the clinical symptoms and make it difficult to identify the underlying 
pathology based only on clinical phenotype changes. In this context, the systematic 
assessment of CSF biomarkers may be of help, also suggesting the possibility to adopt a 
different nomenclature for identifying distinct disease-associated processes rather than the 
single disease. 
In view of available disease-modifying drugs able to directly interfere with the 
etiopathogenetic events – ie, anti-amyloid agents; inhibitors of tau or -syn phosphorylation, 
etc. - early diagnosis is mandatory for all neurodegenerative diseases. This concept is even 
more important when considering clinically heterogeneous disorders as PD is. At present, 
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we have promising candidate biomarkers, which also guarantee to reliably exclude other 
diagnoses than PD. 
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